"The numbers are fantastic," said Dr Fred Locke, a blood cancer expert at Moffitt Cancer Center in Tampa who co-led the study.

"These are heavily treated patients who have no other options."

The treatment, which has been dubbed 'a living drug' by doctors, works by filtering a patient's blood to remove key immune system cells called T-cells, which are then genetically engineered in the lab to recognise cancer cells.

Cancer cells are very good a evading the immune system, but the new therapy essentially cuts the brakes, allowing immune cells to do their job properly.

Martin Ledwick, Cancer Research UKs head cancer information nurse, said: These results are promising and suggest that one day CAR-T cells could become a treatment option for some patients with certain types of lymphoma.

"But, we need to know more about the side effects of the treatment and long term benefits.

The rest is here:

Terminal cancer patients in complete remission after one gene therapy treatment - Telegraph.co.uk